CuraTeQ Biologics

𝗖𝘂𝗿𝗮𝗧𝗲𝗤 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 (a wholly owned subsidiary of Aurobindo Pharma Ltd.) is an 𝗘𝗨 𝗚𝗠𝗣 𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 biopharmaceutical company headquartered in Hyderabad, India. Our vision is to improve the wellbeing of patients suffering from debilitating illnesses by providing them access to high quality and cost-effective biosimilars. CuraTeQ has a development pipeline of 14 biosimilars, of which, three products have been filed with EMA, one product has been filed with MHRA, and four more products are in global phase 3 clinical trials. - 𝗕𝗲𝘃𝗾𝗼𝗹𝘃𝗮™, (Bevacizumab biosimilar), has received UK MHRA approval. - 𝗭𝗲𝗳𝘆𝗹𝘁𝗶™, (Filgrastim biosimilar), has received EMA approval. - 𝗗𝗮𝘇𝘂𝗯𝗹𝘆𝘀™, (Trastuzumab biosimilar), has received CDSCO approval in India, and is under review with EMA. 𝗢𝘂𝗿 𝗠𝗶𝘀𝘀𝗶𝗼𝗻: ● Deliver exceptional value to stakeholders and better health outcomes to patients by becoming a leading global biosimilars developer by 2030. ● Build deep capabilities in development and manufacturing to deliver quality and cost-effective biosimilars for patients across the globe. ● Create a sustainable and broad portfolio of biosimilars with a focus on oncology and immunology therapies.